VP1 372-380 (HLA-B*07:02)
( VPQYGYLTL )
This peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays
| Sequence: | VPQYGYLTL | |
| Gene: | VP1 | |
| Delivery: | 3 weeks | |
| C-Terminus: | OH | |
| N-Terminus: | H | |
| Amount: | 1 mg | |
| Counter Ion: | TFA | |
| Protein: | Major capsid protein VP1 | |
| Species: | (HBoV1) (Human bocavirus type 1) | |
| Allele: | HLA-B*07:02 | |
| Application : | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response | |
| Indication : | Cancer;Gene therapy | |
| Purity : | 95% HPLC-MS |
Protocols and Tips
Data sheets
Safety data sheet poly peptides:For your convenience, we have compiled a selection of publications
where our peptide products have been employed:
Publications >
€60.40*
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity: 95% HPLC-MS